NextCure, Inc.
NextCure, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative immunomedicines to treat cancer. The company focuses on patients who do not respond to current therapies, whose cancer progresses despite treatment, and those with cancer types not adequately addressed by available therapies. NextCure leverages its proprietary FIND-IOTM technology to identify novel targets and develop therapies that modulate immune responses within the tumor microenvironment, aiming to restore anti-tumor activity and address significant unmet medical needs.
NextCure, Inc.
9000 Virginia Manor Road, Suite 200, Beltsville, MD 20705, USA
What We Do
NextCure's proprietary platform uses functional assessments of immune pathways to identify proteins that can be targeted with novel immunomedicines, aiming to repair and maintain anti-tumor immunity.
NextCure develops therapeutics that improve immune function, overcoming resistance and lack of responses to current immunotherapies. The company integrates all aspects of development to improve outcomes by eliminating traditional silos.
NextCure seeks strategic partnerships to develop biologic-based therapeutics for cancer, autoimmune, and neurological disorders, exploring in-licensing opportunities for late-stage clinical assets.
An antibody-drug conjugate targeting B7-H4 on tumors, designed to reduce toxicity while improving tumor killing. It is advancing towards an IND by the end of 2024.
A first-in-class immunomedicine designed to block immune suppression mediated by LAIR-1, showing evidence of clinical activity in hard-to-treat cancers.
A monoclonal antibody targeting LAIR-1 to induce killing of AML blast cells and leukemic stem cells, currently in a Ph1 dose escalation study in AML.
Application Area
Drugs
Key People
President & CEO
General Counsel